期刊
NUCLEAR MEDICINE AND BIOLOGY
卷 31, 期 6, 页码 753-759出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nucmedbio.2004.04.002
关键词
DOTA-lanreotide; Lu-177; A-431 cell lines; targeted therapy
Lu-177 of specific activity similar to 100-110 TBq/g and radionuclidic purity of similar to 100% was obtained by irradiation of enriched Lu2O3 (60.6% Lu-176) target for 7 days at a thermal neutron flux of 3 x 10(13) n/cm(2)/sec. The Lu-177 labeling of a macrocyclic bifunctional chelating agent viz. 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) has been extensively studied. Lanreotide, [beta-naphthyl-Ala-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2] a disulfide-linked cyclic octapeptide and a somatostatin analog, reported to bind with a wide variety of tumors expressing somatostatin receptors, was conjugated with DOTA. The peptide-BFCA conjugate was characterized with the help of high-resolution two-dimensional proton NMR spectroscopy. The Lu-177 labeling of the DOTA-lanreotide conjugate has been standardized to give a radiolabeling yield of 85%. The tracer showed specific binding with A-431 human epidermoid carcinoma and IMR-32 human brain neuroblastoma cells. (C) 2004 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据